Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 3Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Glioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Advanced or Metastatic ER+ Breast Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

thymoglobulin 2Thiotepa 2Stem Cell Transplantation 2Melphalan 2Ifosfamide 2Etoposide 2Bone Marrow Transplantation 2Antilymphocyte Serum 2sodium thiosulfate 1ribociclib 1omburtamab I-131 1lexatumumab 1ganitumab 1fludarabine phosphate 1copanlisib 1bempegaldesleukin 1X-Rays 1Vincristine 1Topotecan 1Temozolomide 1Tacrolimus 1Specimen Handling 1Rituximab 1Receptor Protein-Tyrosine Kinases 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Polymerase Chain Reaction 1Platinum 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rhabdomyosarcoma × ribociclib × Clear all
NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Novartis

Phase 1 Terminated
12 enrolled
CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡